Profile data is unavailable for this security.
About the company
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company’s R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
- Revenue in INR (TTM)1.32bn
- Net income in INR33.80m
- Incorporated1976
- Employees423.00
- LocationLyka Labs Ltd101 - Shiv Shakti Industrial EstateAndheri Kurla Road, Andheri (East)MUMBAI 400036IndiaIND
- Phone+91 2 266112200
- Fax+91 2 266112248
- Websitehttp://www.lykalabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brooks Laboratories Ltd | 781.93m | -198.55m | 3.64bn | 293.00 | -- | 6.15 | -- | 4.65 | -7.68 | -7.68 | 30.13 | 22.56 | 0.7934 | 5.44 | 3.96 | 2,668,713.00 | -20.15 | -13.86 | -27.57 | -22.90 | 31.35 | 26.19 | -25.40 | -27.47 | 0.9891 | 0.0688 | 0.1318 | -- | 25.76 | 7.63 | 6.26 | -- | -12.73 | -- |
| Medico Remedies Ltd | 1.41bn | 76.77m | 3.70bn | 193.00 | 48.74 | 6.67 | 34.83 | 2.62 | 0.9159 | 0.9159 | 16.88 | 6.69 | 1.40 | 6.35 | 2.63 | 7,318,264.00 | 7.63 | 6.15 | 14.54 | 12.40 | 26.19 | 25.26 | 5.44 | 3.99 | 1.40 | 11.24 | 0.1705 | -- | 3.19 | 8.21 | 14.49 | 39.49 | -7.58 | -- |
| Venus Remedies Ltd. | 6.15bn | 221.01m | 3.99bn | 1.19k | 18.04 | 0.8078 | 8.50 | 0.6495 | 16.56 | 16.56 | 461.13 | 369.72 | 0.945 | 2.68 | 8.72 | 5,178,093.00 | 3.40 | 4.82 | 4.06 | 6.17 | 39.06 | 38.90 | 3.60 | 5.58 | 2.69 | 1,660.39 | 0.0765 | -- | 8.27 | 13.32 | 7.25 | -- | 6.38 | -- |
| Kilitch Drugs (India) Ltd | 1.58bn | 164.61m | 4.92bn | 168.00 | 29.78 | 2.60 | 28.38 | 3.12 | 10.28 | 10.28 | 98.44 | 117.72 | 0.6347 | 26.77 | 2.29 | 9,377,369.00 | 5.70 | 3.38 | 7.93 | 4.76 | 34.75 | 35.33 | 8.98 | 6.17 | 2.01 | 2.81 | 0.1467 | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| ZIM Laboratories Ltd | 3.88bn | 161.50m | 5.02bn | 556.00 | 31.14 | 2.07 | 14.80 | 1.29 | 3.31 | 3.31 | 79.19 | 49.82 | 0.9788 | 2.67 | 5.18 | 6,980,632.00 | 4.07 | 3.88 | 5.70 | 6.54 | 53.95 | 47.45 | 4.16 | 3.97 | 0.9475 | 2.77 | 0.3004 | 1.21 | -7.80 | 1.84 | -29.42 | 2.37 | 29.41 | -- |
| Lyka Labs Ltd | 1.32bn | 33.80m | 5.05bn | 423.00 | 153.48 | 5.11 | 40.80 | 3.84 | 0.9226 | 0.9226 | 37.94 | 27.71 | 0.8222 | 6.01 | 3.92 | 3,111,116.00 | 1.95 | -5.48 | 2.50 | -8.30 | 59.65 | 60.82 | 2.38 | -9.16 | 1.23 | 2.34 | 0.2627 | -- | 19.47 | 9.45 | 81.16 | -- | 13.88 | -- |
| Accent Microcell Ltd | 2.62bn | 325.33m | 5.06bn | 174.00 | 12.14 | 2.84 | 14.10 | 1.93 | 19.80 | 19.80 | 141.04 | 84.68 | 1.65 | 4.64 | 6.67 | 15,070,950.00 | 20.43 | -- | 24.77 | -- | 32.30 | -- | 12.41 | -- | 4.81 | -- | 0.0114 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Medicamen Biotech Ltd | 1.82bn | 64.80m | 5.49bn | 378.00 | 60.80 | 2.53 | 39.76 | 3.02 | 7.10 | 7.10 | 165.42 | 170.67 | 0.6199 | 1.67 | 2.76 | 4,804,595.00 | 1.99 | 5.89 | 2.76 | 8.45 | 46.53 | 36.54 | 3.22 | 9.58 | 1.41 | 2.67 | 0.0854 | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| IND Swift Laboratories Ltd | 7.26bn | 3.73bn | 6.07bn | 47.00 | 1.62 | 0.600 | 1.52 | 0.836 | 63.24 | 63.24 | 123.25 | 171.20 | 0.486 | 1.73 | 2.54 | 154,462,200.00 | 25.01 | 5.00 | 29.88 | 6.13 | 46.23 | 41.12 | 51.47 | 8.52 | 3.51 | 7.87 | 0.016 | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Sakar Healthcare Ltd | 1.64bn | 124.03m | 6.20bn | 325.00 | 50.15 | 2.01 | 19.43 | 3.77 | 5.68 | 5.68 | 75.48 | 141.51 | 0.4312 | 3.22 | 7.45 | 5,052,619.00 | 3.25 | 5.26 | 3.85 | 6.28 | 44.83 | 43.47 | 7.55 | 10.12 | 0.6515 | 3.28 | 0.2374 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
